DPP-Ⅳ抑制剂联合胰岛素强化降糖治疗对胰岛修复的影响
| 作者: |
1区觉璋,
1陈淑群,
1黄泽
1 广东省江门市五邑中医院内分泌科，广东 江门 529000 |
| 通讯: |
区觉璋
Email: qujiaozhang1980@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2016.06.001 |
| 基金: | 江门市科技计划项目, 2013019 |
摘要
目的：考察DPP-Ⅳ抑制剂联合胰岛素强化降糖治疗对胰岛修复的影响。方法：选取90例初诊2型糖尿病患者随机分为观察组和对照组，每组45例。观察组患者给予预混型胰岛素早、晚餐前皮下注射治疗，设定靶血糖值(fasting blood glucose，FBG) <6.1 mmol/L，2hPG <7.8 mmol/L，沙格列汀起始剂量5 mg/次，1次/d。对照组给予胰岛素早预混型胰岛素早、晚餐前皮下注射治疗，设定靶血糖值FBG <6.1 mmol/L，2hPG <7.8 mmol/L，安慰剂1次/d。比较两组患者血糖水平、血脂水平、糖化血红蛋白(hemoglobin A1c，HbA1C)、胰岛β细胞功能(HOMA-β)和胰岛素抵抗指数(HOMA-IR)差异。结果：治疗前两组患者各指标差异无统计学意义(P>0.05)，治疗12周后，观察组患者血糖水平显著低于对照组患者(t=1.756，t=2.369，P<0.05)，血脂水平与对照组患者比较差异无统计学意义(P>0.05)。观察组患者治疗后HOMA-β显著高于对照组，且HbA1C、HOMA-IR水平显著低于对照组(t=2.219，t=1.896，t=1.934，P<0.05)。结论：DPP-Ⅳ抑制剂联合胰岛素强化降糖治疗可以更好地修复胰岛功能。
关键词：
糖尿病
胰岛抵抗
DPP-Ⅳ抑制剂
Effect of DPP-Ⅳ inhibitor combined with insulin intensive therapy on pancreatic islet repair
CorrespondingAuthor: OU Juezhang Email: qujiaozhang1980@163.com
DOI: 10.3978/j.issn.2095-6959.2016.06.001
Abstract
Objective: To investigate the effect of DPP-Ⅳ inhibitor combined with insulin intensive therapy on pancreatic islet repair. Methods: 90 patients with newly diagnosed type 2 diabetic patients were randomly divided into observation group and control group, 45 cases in each group. The observation group were treated with subcutaneous injection of pre-mixed insulin before breakfast and dinner, setting target blood glucose value FBG <6.1 mmol/L, 2hPG <7.8 mmol/L, onglyza 5 mg/d. The control group received subcutaneous injection of insulin before breakfast and dinner therapy, set the target blood glucose value 2hPG <7.8 mmol/L, FBG <6.1 mmol/L, and placebo. Blood glucose level, blood lipid levels, glycosylated hemoglobin (HbA1C), islet cell function (HOMA-β) and insulin resistance index (HOMA-IR) were compared between the two groups. Results: There was no significant difference for all indexes between the two groups before treatment (P>0.05). After 12 weeks, the blood glucose level in the observation group was significantly lower than that in the control group (t=1.756, t=2.369, P<0.05), the difference of blood liquid was not statistically significant (P>0.05). After treatment, the HOMA-β was significantly higher in the observation group than that in the control group, and the level of HbA1C and HOMA-IR was significantly lower than that in the control group (t=2.219, t=1.896, t=1.934, P<0.05). Conclusion: DPP-Ⅳ inhibitor combined with insulin intensive therapy can improve the function of pancreatic islet in patients with type 2 diabetes.